PPIDT00004
Drug Information
| Name | Denileukin diftitox |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB00004 |
| Type | biotech |
| Indication | Denileukin diftitox was previously indicated for the treatment of adult patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.[L26381] It is also indicated for the treatment of adult patients with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy.[L51254] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravenous |
150 ug/1mL
|